

Supplemental Table 1. Causes of Grade 3+ Infections During Study Treatment

	Allo		Auto		Chemo		Total		Total
	Placebo	TXA	Placebo	TXA	Placebo	TXA	Placebo	TXA	
	(n= 65)	(n= 63)	(n= 36)	(n= 34)	(n= 62)	(n= 66)	(n= 163)	(n= 163)	
Infections (Grade 3+)	19 (29.2)	12 (19.0)	5 (13.9)	1 (2.9)	22 (35.5)	16 (24.2)	46 (28.2)	29 (17.8)	75 (23.0)
Other infection	12 (18.5)	9 (14.3)	2 (5.6)	0 (0.0)	13 (21.0)	9 (13.6)	27 (16.6)	18 (11.0)	45 (13.8)
Lung infection	2 (3.1)	2 (3.2)	1 (2.8)	0 (0.0)	6 (9.7)	4 (6.1)	9 (5.5)	6 (3.7)	15 (4.6)
Sepsis	4 (6.2)	0 (0.0)	2 (5.6)	0 (0.0)	2 (3.2)	2 (3.0)	8 (4.9)	2 (1.2)	10 (3.1)
Skin infection	3 (4.6)	1 (1.6)	0 (0.0)	0 (0.0)	4 (6.5)	0 (0.0)	7 (4.3)	1 (0.6)	8 (2.5)
Sinusitis	0 (0.0)	1 (1.6)	0 (0.0)	0 (0.0)	2 (3.2)	1 (1.5)	2 (1.2)	2 (1.2)	4 (1.2)
Upper respiratory infection	0 (0.0)	1 (1.6)	0 (0.0)	0 (0.0)	1 (1.6)	1 (1.5)	1 (0.6)	2 (1.2)	3 (0.9)
Catheter related infection	0 (0.0)	0 (0.0)	0 (0.0)	1 (2.9)	1 (1.6)	0 (0.0)	1 (0.6)	1 (0.6)	2 (0.6)
Soft tissue infection	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.6)	1 (1.5)	1 (0.6)	1 (0.6)	2 (0.6)
Kidney infection	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.5)	0 (0.0)	1 (0.6)	1 (0.3)
Meningitis	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.6)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Salivary gland infection	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Small intestine infection	1 (1.5)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Urinary tract infection	0 (0.0)	0 (0.0)	0 (0.0)	0 (0.0)	1 (1.6)	0 (0.0)	1 (0.6)	0 (0.0)	1 (0.3)
Sepsis or bacteremia ¹	13 (20.0)	8 (12.7)	4 (11.1)	0 (0.0)	12 (19.4)	11 (16.7)	29 (17.8)	19 (11.7)	48 (15.7)

¹ Bacteremia adverse events are a subset of the "other infection" adverse events, identified by reviewing the verbatim descriptions

ATREAT Flow Diagram

Enrollment

Assessed for eligibility (n=3120)

Excluded (n=2764)
 Not meeting inclusion criteria (n=1002)
 Meeting exclusion criteria (n=1058)
 History of arterial or venous TE (n=727)
 Anti-coagulant therapy (n=242)
 Elevated platelet transfusion threshold (n=130)
 MD refusal (n=98)
 Other (n=256)
 Declined consent (n=816)

Enrolled (n=356)

Not randomized (n=19)
 Lost eligibility (n=14)
 Withdrew (n=5)

Randomized (n=337)

Placebo

n=169

TXA

n=168

Activated (n=165)
 Randomized, not activated (n=4)
 Received study drug (n=163)
 Activated, did not receive study drug (n=2)

Allocation

Activated (n=165)
 Randomized, not activated (n=3)
 Received study drug (n=163)
 Activated, did not receive study drug (n=2)

Completed 30-day follow-up (n=156)
 Completed 120-day follow-up (n=138)

Follow-Up

Completed 30-day follow-up (n=159)
 Completed 120-day follow-up (n=141)

Analyzed (n=163)
 Excluded from analysis (n=2)
 Due to not receiving study drug (n=2)

Analysis

Analyzed (n=163)
 Excluded from analysis (n=2)
 Due to not receiving study drug (n=2)

Supplemental Figure 1 : Recruitment, Enrollment, Randomization and Follow-up in the A-TREAT trial.